Noradrenalina Basi (Noradrenaline Tartrate)

Norepinephrine binds directly to alpha‑1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction and increasing systemic vascular resistance. It also activates beta‑1 receptors in the heart, modestly enhancing cardiac contractility and rate, together resulting in an overall rise in mean arterial pressure.

The dose of Noradrenalina Basi is individualized by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosing is typically titrated intravenously under continuous monitoring in an intensive‑care setting.

Safety data for norepinephrine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Norepinephrine is considered the first‑line vasopressor for most forms of shock because of its balanced alpha‑ and beta‑adrenergic activity, providing potent vasoconstriction with modest cardiac stimulation. Alternatives such as phenylephrine lack beta‑1 activity, while dopamine has a broader dose‑dependent profile, which can lead to more tachyarrhythmias.

Noradrenalina Basi should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability until it is prepared for intravenous administration.

The product is supplied as a sterile injectable solution for intravenous infusion. It is typically administered via a controlled infusion pump, allowing precise titration of the infusion rate based on real‑time blood pressure and hemodynamic monitoring.

Serious risks include severe hypertension, cardiac ischemia, tissue necrosis at the infusion site, and pulmonary edema. Continuous hemodynamic monitoring and careful titration are essential to detect and mitigate these potentially life‑threatening complications.

Patients with known hypersensitivity to norepinephrine or its excipients, uncorrected pheochromocytoma, or those in whom excessive vasoconstriction could be harmful should not receive the product. Contra‑indications must be confirmed by the treating physician before initiation.